keyword
MENU ▼
Read by QxMD icon Read
search

Dmard therapy

keyword
https://www.readbyqxmd.com/read/29045964/-increased-serum-c-c-chemokine-ligand-19-levels-correlated-with-b-cell-abnormalities-in-systemic-lupus-erythematosus
#1
H J Liu, L J Shi, F L Hu, H H Yao, Z G Li, Y Jia
OBJECTIVE: To detect the levels of serum C-C chemokine ligand 19 (CCL19) in patients with systemic lupus erythematosus (SLE) and to evaluate the correlation between CCL19 expression and clinical features and laboratory parameters, trying to reveal the possible role of CCL19 in the pathogenesis of systemic lupus erythematosus. METHODS: The levels of serum CCL19 were measured by enzyme linked immunosorbent assay (ELISA) in 90 patients with SLE and 30 healthy controls...
October 18, 2017: Beijing da Xue Xue Bao. Yi Xue Ban, Journal of Peking University. Health Sciences
https://www.readbyqxmd.com/read/29033678/quantitative-metabolic-volumetric-product-on-18-fluorine-2fluoro-2-deoxy-d-glucose-positron-emission-tomography-computed-tomography-in-assessing-treatment-response-to-disease-modifying-antirheumatic-drugs-in-rheumatoid-arthritis-multiparametric-analysis-integrating
#2
Nandigam Santosh Kumar, Yogesh Shejul, Ramesh Asopa, Sandip Basu
The purpose of this study was to assess the role of fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography (FDG-PET/CT) in the evaluation of treatment response evaluation to disease-modifying antirheumatic drug (DMARD) therapy in patients of rheumatoid arthritis (RA). A total of ten patients with proven diagnosis of RA as per the 2010 American College of Rheumatology/European League against Rheumatism (EULAR) criteria were prospectively evaluated. All patients underwent clinical and biochemical evaluation and a baseline FDG-PET/CT with assessment of maximum standardized uptake value and metabolic volumetric product (MVP) values...
October 2017: World Journal of Nuclear Medicine
https://www.readbyqxmd.com/read/29032909/subclinical-synovitis-measured-by-ultrasound-in-rheumatoid-arthritis-patients-with-clinical-remission-induced-by-synthetic-and-biological-modifying-disease-drugs
#3
Marcos Cruces, Soham Al Snih, Natalí Serra-Bonett, Juan C Rivas
BACKGROUND: Rheumatoid arthritis (RA) patients with disease in clinical remission might show subclinical synovitis, which can be related to the progress of structural joint damage. OBJECTIVE: To determine and compare the degree of synovial inflammation by ultrasound (US) in patients with RA in clinical remission, treated with DMARD or combination therapy with DMARD and anti-TNF. METHODS: Hospital-based cross-sectional study of 58 patients with RA in sustained remission for at least 6 months by DAS28 <2...
October 9, 2017: Reumatología Clinica
https://www.readbyqxmd.com/read/29029185/patient-reported-outcomes-in-newly-diagnosed-early-rheumatoid-arthritis-patients-treated-to-target-with-a-tocilizumab-or-methotrexate-based-strategy
#4
Xavier M Teitsma, Johannes W G Jacobs, Paco M J Welsing, Attila Pethö-Schramm, Michelle E A Borm, Lidy Hendriks, Natasja H A M Denissen, Jacob M van Laar, Floris P J G Lafeber, Johannes W J Bijlsma
Objective: To evaluate the effect of initiation of tocilizumab, with or without MTX, compared with MTX alone on patient-reported outcomes (PROs), in DMARD-naïve patients with early RA. Methods: In U-Act-Early, patients initiated treat-to-target step-up MTX, tocilizumab or tocilizumab plus MTX therapy. PROs assessed included the Functional Assessment of Chronic Illness Therapy-Fatigue, 36-item Short Form (SF-36), five dimensional EuroQol (EQ-5D) and the Revised Illness Perception Questionnaire...
September 23, 2017: Rheumatology
https://www.readbyqxmd.com/read/28976302/certolizumab-pegol-and-secukinumab-for-treating-active-psoriatic-arthritis-following-inadequate-response-to-disease-modifying-antirheumatic-drugs-a-systematic-review-and-economic-evaluation
#5
Mark Corbett, Fadi Chehadah, Mousumi Biswas, Thirimon Moe-Byrne, Stephen Palmer, Marta Soares, Matthew Walton, Melissa Harden, Pauline Ho, Nerys Woolacott, Laura Bojke
BACKGROUND: Several biologic therapies are approved by the National Institute for Health and Care Excellence (NICE) for psoriatic arthritis (PsA) patients who have had an inadequate response to two or more synthetic disease-modifying antirheumatic drugs (DMARDs). NICE does not specifically recommend switching from one biologic to another, and only ustekinumab (UST; STELARA(®), Janssen Pharmaceuticals, Inc., Horsham, PA, USA) is recommended after anti-tumour necrosis factor failure. Secukinumab (SEC; COSENTYX(®), Novartis International AG, Basel, Switzerland) and certolizumab pegol (CZP; CIMZIA(®), UCB Pharma, Brussels, Belgium) have not previously been appraised by NICE...
October 2017: Health Technology Assessment: HTA
https://www.readbyqxmd.com/read/28963724/the-anti-cd6-antibody-itolizumab-provides-clinical-benefit-without-lymphopenia-in-rheumatoid-arthritis-patients-results-from-a-6-month-open-label-phase-i-clinical-trial
#6
Pedro C Rodríguez, Dinorah M Prada, Ernesto Moreno, Lazaro E Aira, Claudino Molinero, Ana M Lopez, Jorge A Gómez, Isabel M Hernandez, Jose P Martinez, Yusimi Reyes, Joel M Milera, Maria V Hernandez, Roberto Torres, Yisel Avila, Yinet Barrese, Carmen Viada, Enrique Montero, Patricia Hernández
Itolizumab is a humanized anti-CD6 monoclonal antibody (mAb) that has previously shown encouraging results, in terms of safety and positive clinical effects, in a 6-week monotherapy clinical trial conducted in RA patients. The current phase I study evaluated the safety and clinical response for a longer treatment of 12 itolizumab intravenous doses in subjects with active RA despite previous DMARD therapy. Twenty one subjects were enrolled in four dose groups (0.1, 0.2, 0.4 and 0.8 mg/kg). Efficacy endpoints including American College of Rheumatology (ACR)20, ACR50 and ACR70 response rates and Disease Activity Score in 28 joints (DAS28) were monitored at baseline and at specific time points over a 10-week follow-up period...
September 30, 2017: Clinical and Experimental Immunology
https://www.readbyqxmd.com/read/28952204/disease-activity-trajectories-in-early-rheumatoid-arthritis-following-intensive-dmard-therapy-over-3-years-association-with-persistence-to-therapy
#7
Nasir Wabe, Jessica Wojciechowski, Mihir D Wechalekar, Leslie G Cleland, Leah McWilliams, Anita Lee, Susanna Proudman, Michael D Wiese
OBJECTIVE: To identify the disease activity trajectories during intensive triple disease modifying anti-rheumatic drug (DMARD) therapy over 3 years in rheumatoid arthritis (RA) patients and to evaluate the association with treatment persistence. METHODS: Disease Activity Score in 28 joints, baseline risk factors and medication usage were obtained from a longitudinal observational cohort of early RA patients, most of whom were treated with combination DMARD therapy consisting of methotrexate, sulfasalazine and hydroxychloroquine...
September 26, 2017: International Journal of Rheumatic Diseases
https://www.readbyqxmd.com/read/28947313/effectiveness-of-biologic-and-non-biologic-antirheumatic-drugs-on-anaemia-markers-in-153-788-patients-with-rheumatoid-arthritis-new-evidence-from-real-world-data
#8
Sanjoy Ketan Paul, Olga Montvida, Jennie H Best, Sara Gale, Attila Pethoe-Schramm, Khaled Sarsour
BACKGROUND: To evaluate the impact of treatment with disease-modifying antirheumatic drugs (DMARDs), including IL-6 receptor inhibitor tocilizumab (TCZ), on anaemia markers in patients with rheumatoid arthritis. METHODS: Using the Centricity Electronic Medical Records from USA, patients with rheumatoid arthritis diagnosed between January 2000 and April 2016, who initiated TCZ (n = 3732); tofacitinib (TOFA, n = 3126); other biologic DMARD (obDMARD, n = 55,964); or other non-biologic DMARD (onbDMARD, n = 91,236) were identified...
August 3, 2017: Seminars in Arthritis and Rheumatism
https://www.readbyqxmd.com/read/28944162/an-update-on-treatment-of-pediatric-chronic-non-infectious-uveitis
#9
Arjun B Sood, Sheila T Angeles-Han
There are no standardized treatment protocols for pediatric non-infectious uveitis. Topical corticosteroids are the typical first-line agent, although systemic corticosteroids are used in intermediate, posterior and panuveitic uveitis. Corticosteroids are not considered to be long-term therapy due to potential ocular and systemic side effects. In children with severe and/or refractory uveitis, timely management with higher dose disease-modifying antirheumatic drugs (DMARDs) and biologic agents is important...
March 2017: Current Treatment Options in Rheumatology
https://www.readbyqxmd.com/read/28941147/timing-and-impact-of-decisions-to-adjust-disease-modifying-antirheumatic-drug-therapy-for-rheumatoid-arthritis-patients-with-active-disease
#10
Yomei Shaw, Chung-Chou H Chang, Marc C Levesque, Julie M Donohue, Kaleb Michaud, Mark S Roberts
OBJECTIVE: Guidelines recommend that rheumatoid arthritis (RA) patients with moderate to high disease activity (MHDAS) adjust disease-modifying antirheumatic drug (DMARD) therapy at least every 3 months until reaching low disease activity or remission (LDAS). We examined how quickly RA patients with MHDAS adjust DMARD therapy in clinical practice, and whether those who adjust DMARDs within 90 days in response to MHDAS reach LDAS sooner. METHODS: We identified RA patients with MHDAS in the University of Pittsburgh Rheumatoid Arthritis Comparative Effectiveness Research (RACER) registry, and conducted a competing risks regression on time to DMARD therapy adjustment and a Cox regression on time to LDAS...
September 21, 2017: Arthritis Care & Research
https://www.readbyqxmd.com/read/28937499/prognostic-factors-for-permanent-work-disability-in-patients-with-rheumatoid-arthritis-who-received-combination-therapy-of-conventional-synthetic-disease-modifying-antirheumatic-drugs-a-retrospective-cohort-study
#11
M Luisa Vazquez-Villegas, Jorge I Gamez-Nava, Alfredo Celis, Dalia Sanchez-Mosco, Liliana F de la Cerda-Trujillo, Jessica D Murillo-Vazquez, A Miriam Saldaña-Cruz, Miriam F Alcaraz-Lopez, Valeria Diaz-Rizo, Jose Alvarez-Nemegyei, Mario H Cardiel, Laura Gonzalez-Lopez
BACKGROUND: There is limited information about the factors related with the development of long-term permanent work disability (PWD) in rheumatoid arthritis (RA) treated with a combination of conventional synthetic disease-modifying antirheumatic drugs (cs-DMARDs). OBJECTIVE: The aim of this study was to evaluate incidence and factors associated with the development of PWD in RA treated with combination therapy using conventional synthetic cs-DMARDs. METHODS: We assessed in multivariate models the effect of clinical and demographic factors in the development of PWD in a long-term retrospective cohort of 180 workers with RA who were treated with a combination of cs-DMARDs...
September 21, 2017: Journal of Clinical Rheumatology: Practical Reports on Rheumatic & Musculoskeletal Diseases
https://www.readbyqxmd.com/read/28937473/prognostic-factors-for-permanent-work-disability-in-patients-with-rheumatoid-arthritis-who-received-combination-therapy-of-conventional-synthetic-disease-modifying-antirheumatic-drugs-a-retrospective-cohort-study
#12
M Luisa Vazquez-Villegas, Jorge I Gamez-Nava, Alfredo Celis, Dalia Sanchez-Mosco, Liliana F de la Cerda-Trujillo, Jessica D Murillo-Vazquez, A Miriam Saldaña-Cruz, Miriam F Alcaraz-Lopez, Valeria Diaz-Rizo, Jose Alvarez-Nemegyei, Mario H Cardiel, Laura Gonzalez-Lopez
BACKGROUND: There is limited information about the factors related with the development of long-term permanent work disability (PWD) in rheumatoid arthritis (RA) treated with a combination of conventional synthetic disease-modifying antirheumatic drugs (cs-DMARDs). OBJECTIVE: The aim of this study was to evaluate incidence and factors associated with the development of PWD in RA treated with combination therapy using conventional synthetic cs-DMARDs. METHODS: We assessed in multivariate models the effect of clinical and demographic factors in the development of PWD in a long-term retrospective cohort of 180 workers with RA who were treated with a combination of cs-DMARDs...
October 2017: Journal of Clinical Rheumatology: Practical Reports on Rheumatic & Musculoskeletal Diseases
https://www.readbyqxmd.com/read/28927869/what-have-we-learned-from-best
#13
Cornelia F Allaart, Iris M Markusse, Willem F Lems
BACKGROUND: How have the long term outcomes of RA improved in the last decade? METHODS: Patients with DMARD naïve RA were randomized to 4 treatment strategies: 1. sequential DMARD monotherapy, 2. step-up combination therapy, 3. initial combination therapy including prednisone or 4. including infliximab. Treatment-to-target was aimed at DAS≤2.4 (three-monthly calculations). Functional ability (HAQ), radiologic damage progression (Sharp/vanderHeijde Score) and overall survival were reported...
September 16, 2017: Clinical Immunology: the Official Journal of the Clinical Immunology Society
https://www.readbyqxmd.com/read/28923098/patient-reported-outcomes-of-baricitinib-in-patients-with-rheumatoid-arthritis-and-no-or-limited-prior-disease-modifying-antirheumatic-drug-treatment
#14
Michael Schiff, Tsutomu Takeuchi, Roy Fleischmann, Carol L Gaich, Amy M DeLozier, Douglas Schlichting, Wen-Ling Kuo, Ji-Eon Won, Tara Carmack, Terence Rooney, Patrick Durez, Saeed Shaikh, Rodolfo Pardo Hidalgo, Ronald van Vollenhoven, Cristiano A F Zerbini
BACKGROUND: This study evaluates patient-reported outcomes (PROs) in a double-blind, phase III study of baricitinib as monotherapy or combined with methotrexate (MTX) in patients with active rheumatoid arthritis (RA) with no or minimal prior conventional synthetic disease-modifying antirheumatic drugs (DMARDs) and naïve to biological DMARDs. METHODS: Patients were randomized 4:3:4 to MTX administered once weekly (N = 210), baricitinib monotherapy (4 mg once daily (QD), N = 159), or combination of baricitinib (4 mg QD) and MTX (baricitinib + MTX, N = 215)...
September 18, 2017: Arthritis Research & Therapy
https://www.readbyqxmd.com/read/28917375/total-glucosides-of-paeony-for-rheumatoid-arthritis-a-systematic-review-of-randomized-controlled-trials
#15
REVIEW
Jing Luo, Di-Er Jin, Guo-Yan Yang, Ying-Ze Zhang, Jian-Ming Wang, Wei-Ping Kong, Qing-Wen Tao
BACKGROUND: Total glucosides of paeony (TGP) is commonly used to treat rheumatoid arthritis (RA) in China. However, clinical practice hasn't been well informed by evidence from appropriately conducted systematic reviews. This PRISMA-compliant systematic review aims at examining the effectiveness and safety of TGP for RA. METHODS: Randomized controlled trials (RCTs) comparing TGP with placebo, no treatment, or disease-modifying antirheumatic drugs (DMARDs) for patients with RA were retrieved by searching seven databases...
October 2017: Complementary Therapies in Medicine
https://www.readbyqxmd.com/read/28905133/rabbit-risk-score-and-icu-admission-due-to-infection-in-patients-with-rheumatoid-arthritis
#16
Herwig Pieringer, Rainer Hintenberger, Erich Pohanka, Clemens Steinwender, Jens Meier, Franz Gruber, Lorenz Auer-Hackenberg
Rheumatoid arthritis (RA) patients are at increased risk of infection. Aim of the present study was to investigate whether RA patients admitted to an intensive care unit (ICU) due to infection have higher Rheumatoid Arthritis Observation of Biologic Therapy (RABBIT) risk scores compared to control RA patients. Seventy-four RA patients (32.4% male) admitted to an ICU due to infection (from January 2002 to December 2013) and 74 frequency-matched control RA patients (16.2% male) were included in this cross-sectional study...
November 2017: Clinical Rheumatology
https://www.readbyqxmd.com/read/28903543/biosimilars-in-rheumatology-a-review-of-the-evidence-and-their-place-in-the-treatment-algorithm
#17
REVIEW
Hendrik Schulze-Koops, Alla Skapenko
Determining biosimilarity involves a comprehensive exercise with a focus on determining the comparability of the molecular characteristics and preclinical profile of the biosimilar and reference product, such that there is less need for extensive clinical testing to assure comparability of clinical outcomes. Three anti-TNF biosimilar agents are approved for patients with rheumatic diseases in the European Union. The infliximab (Remicade®) biosimilars CT-P13 (Remsima® and Inflectra®) and SB2 (Flixabi®) and the etanercept (Enbrel®) biosimilar SB4 (Benepali®) have shown close comparability to their reference medicinal products, having undergone extensive evaluations...
August 1, 2017: Rheumatology
https://www.readbyqxmd.com/read/28863153/triple-dmard-treatment-in-early-rheumatoid-arthritis-modulates-synovial-t-cell-activation-and-plasmablast-plasma-cell-differentiation-pathways
#18
Alice M Walsh, Mihir D Wechalekar, Yanxia Guo, Xuefeng Yin, Helen Weedon, Susanna M Proudman, Malcolm D Smith, Sunil Nagpal
OBJECTIVES: This study sought to investigate the genome-wide transcriptional effects of a combination of disease modifying anti-rheumatic drugs (tDMARD; methotrexate, sulfasalazine and hydroxychloroquine) in synovial tissues obtained from early rheumatoid arthritis (RA) patients. While combination DMARD strategies have been investigated for clinical efficacy, very little data exists on the potential molecular mechanism of action. We hypothesized that tDMARD would impact multiple biological pathways, but the specific pathways were unknown...
2017: PloS One
https://www.readbyqxmd.com/read/28862177/effect-of-disease-modifying-antirheumatic-drug-therapy-on-immune-response-to-trivalent-influenza-vaccine-in-rheumatoid-arthritis
#19
Vikramraj K Jain, Nandhini Bhashini, L Karthik Balajee, Sujatha Sistla, Subhash Chandra Parija, Vir Singh Negi
BACKGROUND & OBJECTIVES: Patients with autoimmune rheumatic diseases may be at an increased risk of infection due to disease and use of disease-modifying antirheumatic drug (DMARD) therapy. The present study was done to evaluate the immune response to influenza vaccination in patients with rheumatoid arthritis (RA). METHODS: Fifty one RA patients on stable methotrexate (MTX) therapy (≥15 mg/wk), 51 newly diagnosed DMARD-naïve RA patients and 45 healthy controls received a single dose of inactivated seasonal trivalent influenza vaccine...
April 2017: Indian Journal of Medical Research
https://www.readbyqxmd.com/read/28861167/can-rheumatoid-arthritis-ever-cease-to-exist-a-review-of-various-therapeutic-modalities-to-maintain-drug-free-remission
#20
Di Liu, Na Yuan, Guimei Yu, Ge Song, Yan Chen
Therapies for rheumatoid arthritis (RA) were mostly aimed at reducing the pain, stiffness and further progression of joint destruction. However, with the advent of biologic agents that act against specific inflammatory cytokines contributing to RA pathogenesis (treat-to-target strategy), the degree of remission achieved has been remarkably impressive. In particular, inhibition of tumor necrosis factor α (TNFα), interleukins-1 and -6 and receptor-activator of nuclear kappa B ligand by neutralizing antibodies in early diagnosed RA patients has resulted in lowering of disease activity to levels that enable them to function as in the pre-disease stage...
2017: American Journal of Translational Research
keyword
keyword
2404
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"